4. Shim JH, Son YJ, Lee SS, Park KS, Oh HB, Park YD. Ecological study on poisonous snake and investigation of the venom characteristics, snakebiting frequency in Korea. Korean J Environ Ecol 1998;12:58-77.
6. Weinstein SA, White J, Keyler DE, Warrell DA. Non-front-fanged colubroid snakes: a current evidence-based analysis of medical significance. Toxicon 2013;69:103-113.
7. Ramos OH, Selistre-de-Araujo HS. Snake venom metalloproteases: structure and function of catalytic and disintegrin domains. Comp Biochem Physiol C Toxicol Pharmacol 2006;142:328-346.
8. Eble JA. Matrix biology meets toxinology. Matrix Biol 2010;29:239-247.
9. Larréché S, Mion G, Mayet A, Verret C, Puidupin M, Benois A, Petitjeans F, Libert N, Goyffon M. Antivenin remains effective against African Viperidae bites despite a delayed treatment. Am J Emerg Med 2011;29:155-161.
10. Escalante T, Rucavado A, Fox JW, Gutierrez JM. Key events in microvascular damage induced by snake venom hemorrhagic metalloproteinases. J Proteomics 2011;74:1781-1794.
11. Sajevic T, Leonardi A, Krizaj I. Haemostatically active proteins in snake venoms. Toxicon 2011;57:627-645.
12. Sohn YD, Hong SY, Cho KS, Choi WS, Song SW, Bae JS, Kim DS, Chung KH. Acute and repeated dose toxicity studies of recombinant saxatilin, a disintegrin from the Korean snake (Gloydius saxatilis). Toxicon 2008;51:406-417.
13. Li QB, Huang GW, Kinjoh K, Nakamura M, Kosugi T. Hematological studies on DIC-like findings observed in patients with snakebite in south China. Toxicon 2001;39:943-948.
14. Lavonas EJ, Ruha AM, Banner W, Bebarta V, Bernstein JN, Bush SP, Kerns WP 2nd, Richardson WH, Seifert SA, Tanen DA, Curry SC, Dart RC. Rocky Mountain Poison and Drug Center, Denver Health and Hospital Authority. Unified treatment algorithm for the management of crotaline snakebite in the United States: results of an evidence-informed consensus workshop. BMC Emerg Med 2011;11:2.
15. Yoo CK, Kim YM, Park MY, Park MS, Park YD, Park KS. Determination of venom toxicity and standardization of venom and antivenin of Korean Agkistrodon spp. Korean J Vet Public Health 1999;23:135-142.
16. Lee BJ, Hong SI, Kim HS, Kim TH, Lee JH, Kim HJ, Ryu BY, Kim HK. Hematological features of coagulopathy and the efficacy of antivenin therapy for a Korean snakebite. J Korean Surg Soc 2007;72:18-26.
17. Warrell DA. Snake bite. Lancet 2010;375:77-88.
18. Theakston RD, Warrell DA, Griffiths E. Report of a WHO workshop on the standardization and control of antivenoms. Toxicon 2003;41:541-557.
19. Dart RC, Hurlbut KM, Garcia R, Boren J. Validation of a severity score for the assessment of crotalid snakebite. Ann Emerg Med 1996;27:321-326.
20. You KM, Kwon WY, Kwon TH, Shin JH, Lee HJ. Optimal dose of antivenin for asymptomatic or minor envenomation patient with Korean viperidae injuries. J Korean Soc Emerg Med 2013;24:420-427.
21. Kim DH, Choe SM, Oh YM, Oh JS, Kyong YY, Choi KH. Clinical significance of delayed re-evaluation in initial symptoms following snakebite injury. J Korean Soc Clin Toxicol 2009;7:97-104.
22. Park EJ, Yoon SK, Ahn JH, Choi SC, Kim GW, Min YG, Lee KJ, Jung HS, Jung YS. Systemic complications occurring after Korean venomous snake bite, with focus on hematologic and neurologic complications. J Korean Soc Clin Toxicol 2009;7:90-96.
23. Jin SC, Lee JW, Yang SJ, Joo MD, Choi WI. Consideration of factors associated with complications and systemic symptoms of snake bites. J Korean Soc Emerg Med 2008;19:686-696.
24. Jun DH, Lee DP, Choi WI. Initial assessment of the snakebites with local effects. J Korean Soc Emerg Med 2004;15:523-530.
25. Kim ES, Choi WJ. Clinical review of venomous snake bite. J Korean Surg Soc 2000;59:433-440.
26. Cho NS, Park J. A clinical analysis of snake bite injury. J Korean Soc Emerg Med 1996;7:405-414.
27. Jang IS, Lee JA, Kim SY, Hyun SC, Park SM, Park JS, Kim GT, Song HS. Clinical features in snake bite. J Korean Soc Emerg Med 1996;7:580-589.
28. Kim GN, Cho SW, Hwang JY. A clinical analysis on venomous snake bite in west-south area of Korea. J Korean Surg Soc 1995;48:824-831.
29. Scharman EJ, Noffsinger VD. Copperhead snakebites: clinical severity of local effects. Ann Emerg Med 2001;38:55-61.
30. Jeon JC, Lee DH, Kwon GY, Kim SJ. Relation of first aid associated with complications after snake bites. J Korean Soc Clin Toxicol 2009;7:105-112.
31. Toschlog EA, Bauer CR, Hall EL, Dart RC, Khatri V, Lavonas EJ. Surgical considerations in the management of pit viper snake envenomation. J Am Coll Surg 2013;217:726-735.
32. Bush SP. Snakebite suction devices don't remove venom: they just suck. Ann Emerg Med 2004;43:187-188.
33. Campbell BT, Corsi JM, Boneti C, Jackson RJ, Smith SD, Kokoska ER. Pediatric snakebites: lessons learned from 114 cases. J Pediatr Surg 2008;43:1338-1341.
34. Han SK, Kim IS, Ryu S, Lee JW, Kim SW, Yoo IS, You YH, Park JS, Min MG. The effectiveness of antivenin in treating snake bites resulting in minimal clinical symptoms. J Korean Soc Emerg Med 2007;18:577-583.
35. Hifumi T, Yamamoto A, Morokuma K, Okada I, Kiriu N, Ogasawara T, Hasegawa E, Kato H, Inoue J, Koido Y, Takahashi M. Clinical efficacy of antivenom and cepharanthine for the treatment of Mamushi (Gloydius blomhoffii) bites in tertiary care centers in Japan. Jpn J Infect Dis 2013;66:26-31.
36. Morokuma K, Kobori N, Fukuda T, Uchida T, Sakai A, Toriba M, Ohkuma K, Nakai K, Kurata T, Takahashi M. Experimental manufacture of equine antivenom against yamakagashi (Rhabdophis tigrinus). Jpn J Infect Dis 2011;64:397-402.
37. Girish KS, Kemparaju K. Overlooked issues of snakebite management: time for strategic approach. Curr Top Med Chem 2011;11:2494-2508.
38. Solano S, Segura A, Leon G, Gutierrez JM, Burnouf T. Low pH formulation of whole IgG antivenom: impact on quality, safety, neutralizing potency and viral inactivation. Biologicals 2012;40:129-133.
39. Otero-Patiño R, Segura A, Herrera M, Angulo Y, Leon G, Gutierrez JM, Barona J, Estrada S, Pereanez A, Quintana JC, Vargas LJ, Gomez JP, Diaz A, Suarez AM, Fernandez J, Ramirez P, Fabra P, Perea M, Fernandez D, Arroyo Y, Betancur D, Pupo L, Cordoba EA, Ramirez CE, Arrieta AB, Rivero A, Mosquera DC, Conrado NL, Ortiz R. Comparative study of the efficacy and safety of two polyvalent, caprylic acid fractionated [IgG and F(ab')2] antivenoms, in Bothrops asper bites in Colombia. Toxicon 2012;59:344-355.
40. Seong WK, Chung GT, Shin KS, Kim HH, Park KS, Oh HB. Immunological characterization of the venoms from Korean snakes of the genus Agkistrodon for therapeutic antivenin production. Korean J Vet Public Health 1999;23:21-31.
41. Gao JF, Wang J, Qu YF, Ma XM, Ji X. Immunoreactivity between venoms and commercial antiserums in four Chinese snakes and venom identification by species-specific antibody. J Immunol Methods 2013;387:211-218.
42. Ariaratnam CA, Meyer WP, Perera G, Eddleston M, Kuleratne SA, Attapattu W, Sheriff R, Richards AM, Theakston RD, Warrell DA. A new monospecific ovine Fab fragment antivenom for treatment of envenoming by the Sri Lankan Russell's viper (Daboia Russelii Russelii): a preliminary dose-finding and pharmacokinetic study. Am J Trop Med Hyg 1999;61:259-265.
43. Otero R, Leon G, Gutierrez JM, Rojas G, Toro MF, Barona J, Rodriguez V, Diaz A, Nunez V, Quintana JC, Ayala S, Mosquera D, Conrado LL, Fernandez D, Arroyo Y, Paniagua CA, Lopez M, Ospina CE, Alzate C, Fernandez J, Meza JJ, Silva JF, Ramirez P, Fabra PE, Ramirez E, Cordoba E, Arrieta AB, Warrell DA, Theakston RD. Efficacy and safety of two whole IgG polyvalent antivenoms, refined by caprylic acid fractionation with or without beta-propiolactone, in the treatment of Bothrops asper bites in Colombia. Trans R Soc Trop Med Hyg 2006;100:1173-1182.
44. Mion G, Ruttimann M, Saissy JM, Olive F. Efficacy of antivenom therapy (Bitis-Echis-Naja) in the treatment of bites by the carpet viper (Echis carinatus). Intensive Care Med 1997;23:Suppl 1. S179.
47. Zengin S, Yilmaz M, Al B, Yildirim C, Yarbil P, Kilic H, Bozkurt S, Kose A, Bayraktaroglu Z. Plasma exchange as a complementary approach to snake bite treatment: an academic emergency department's experiences. Transfus Apher Sci 2013;03. 29. [Epub].
http://dx.doi.org/10.1016/j.transci.2013.03.006
48. Klaewsongkram J. A role of snake antivenom skin test from the allergist's point of view. Acta Trop 2009;109:84-85.
49. Thiansookon A, Rojnuckarin P. Low incidence of early reactions to horse-derived F(ab')(2) antivenom for snakebites in Thailand. Acta Trop 2008;105:203-205.
50. Nuchpraryoon I, Garner P. Interventions for preventing reactions to snake antivenom. Cochrane Database Syst Rev 2000;(2):CD002153.
51. Cannon R, Ruha AM, Kashani J. Acute hypersensitivity reactions associated with administration of crotalidae polyvalent immune Fab antivenom. Ann Emerg Med 2008;51:407-411.
52. Stone SF, Isbister GK, Shahmy S, Mohamed F, Abeysinghe C, Karunathilake H, Ariaratnam A, Jacoby-Alner TE, Cotterell CL, Brown SG. Immune response to snake envenoming and treatment with antivenom; complement activation, cytokine production and mast cell degranulation. PLoS Negl Trop Dis 2013;7:e2326.
53. LoVecchio F, Klemens J, Roundy EB, Klemens A. Serum sickness following administration of Antivenin (Crotalidae) Polyvalent in 181 cases of presumed rattlesnake envenomation. Wilderness Environ Med 2003;14:220-221.
54. Ko JH, Chung WH. Serum sickness. Lancet 2013;381:e1.
56. Ruha AM, Curry SC, Albrecht C, Riley B, Pizon A. Late hematologic toxicity following treatment of rattlesnake envenomation with crotalidae polyvalent immune Fab antivenom. Toxicon 2011;57:53-59.
57. Bush SP, Seifert SA, Oakes J, Smith SD, Phan TH, Pearl SR, Reibling ET. Continuous IV Crotalidae Polyvalent Immune Fab (Ovine) (FabAV) for selected North American rattlesnake bite patients. Toxicon 2013;69:29-37.
58. Kim JJ, Lim YS, Lim HK, Kim JK, Hyun SY, Yang HJ, Lee G. A case report of snake bites during pregnancy. J Korean Soc Emerg Med 2009;20:223-226.
59. Lee JH, Ahn SM, Jung BY. Anticholinesterase treatment for patients with paralytic strabismus following a viper bite. J Korean Ophthalmol Soc 2009;50:1698-1704.